Acting Chief Executive Officer & Chief Medical Officer
Jenny Chen, PhD
Director, Clinical Department
Chen-Fu Liu, PhD
Director, R&D Department
Taylor Hsu
Business Development Director
Kai-Wei Hsueh, PhD
Deputy Director, Clinical Department
Benny T. Hu
Mr. Hu is a well-known entrepreneur and also a professional manager with proactive thinking. He has been investing in China since 1996 starting while he was leading China Development Industrial Bank (CDIB). During the period of 1993-2004, he grew the investment portfolio from $ 250MM to $ 3.0Bn, making CDIB one of Asia′s largest investment companies. He expanded business of the bank to the United States, Great Britain, Japan, Hong Kong, Korea, Australia, and Philippines.
Of the 250 companies invested during tenure, 62 companies had IPOs and 10 were acquired. In 2003, he assumed role as Chairman and Director of Taipei 101, the tallest building in the world when completed in 2004. Mr. Hu is currently Chairman of Senhwa Biosciences, Inc. dedicating to develop first-in-class small molecule drugs used in cancer treatments.
Mr. Hu received a BA from National Taiwan University, an MA from Yale University and an MBA from Wharton School of University of Pennsylvania.
Sarah Chang, CPA
Ms. Chang joined Senhwa in 2013 and is currently Executive Vice President, Chief Finance Officer and Head of Finance and Administration. She brings Senhwa 15 years of experience in finance and accounting. Before joining Senhwa Biosciences, Inc., Ms. Chang was the Vice President of Operating group (CFO&COO) of Hua Nan Investment Trust Corporation, the large mutual fund company in Taiwan. She was Senior Vice President of the Underwriting Department at IBT Securities Co., Ltd. and lead the IPO project and pre-IPO consultation. Ms Chang is a Certified Public Accountant and also worked at Deloitte & Touche.
She graduated with Accounting major from Tunghai University
Jason Huang M.D.
Dr. Huang has been appointed the Acting Chief Executive Officer on January 1, 2025 and he was assumed the Chief Medical Officer position on June 3, 2024. Prior to joining Senhwa Biosciences, he held positions at Janssen as Regional Therapeutic Area Expert, Asia Pacific excluding Japan, concentrating on infectious disease/vaccine and immunology and served as global clinical operation cluster head of Taiwan, Korea and Malaysia. He led the team and participated in over 90 projects in J&J, contributing to drug development endeavors encompassing over a hundred studies. His remarkable leadership and abundant experience in pharmaceutical field had significantly boosted J&J ’s growth.
Apart from Janssen, Dr. Huang also served as the Medical Department Director at Abbott Laboratories Taiwan, and as the CEO and Chief Medical Officer at Ascendo Biotechnology Inc., successfully advancing three primary assets from lead identification to pre-IND status within a 3-year time frame.
Dr. Huang received his Doctor of Medicine (M.D.) degree from Taipei Medical University and a Master in Law from Soochow University.
Jenny Chen, PhD
Dr. Chen joined the Senhwa team in October 2025 and currently serves as Director of the Clinical Department. She is responsible for coordinating and managing clinical operations in the United States and Taiwan, as well as overseeing the design and execution of outsourced clinical studies.
Dr. Chen has extensive experience in the field of clinical trials across multiple therapeutic areas, including oncology (cholangiocarcinoma, liver cancer, lung cancer, breast cancer, ovarian cancer), respiratory diseases, gastroenterology, cardiology, and nephrology. Prior to joining Senhwa, Dr. Chen served at IQVIA, ASLAN, and AstraZeneca, where she was appointed to the Taiwan, Malaysia, Singapore, and China office to initiate, oversee and monitor clinical trial management.
Dr. Chen earned her Ph.D. in Pharmacy from Taipei Medical University and holds a Taiwan pharmacist license.
Chen-Fu Liu, PhD
Dr. Liu joined Senhwa in November, 2017 and appointed as Director leading R&D department. He is well experienced in drug discovery team structure, patent strategy, CMC and formulation development in the pharmaceutical industry for more than 15 years.
Dr. Liu obtained his Ph.D. degree in chemistry from National Taiwan University in 2002. Since then, he joined TaiGen Biotechnology as a post-doc fellow in the department of medicinal chemistry and served as an investigator afterwards. After TaiGen, Dr. Liu accumulated his solid knowledge and experience in the industry with GNT Biotech & Medicals Corporation, GNTbm and took in charge for the CMC & formulation development while 2 drug candidates were at the stage of phase 2b of multi-national and multi-centered clinical operation when he worked in CVie Therapeutics Limited. Dr. Liu also was the member of the steering committee of a joint collaboration between CVie and ScinoPharm on identifying a new generation of heart failure treatment.
Dr. Liu was certificated with Winston & Strawn LLP American Patent Law and University of Washington Seattle, school of law, CASRIP 2015 program (MMOT program). Further, Dr. Liu holds 5 PCT patents and many of his scientific publications were highly recognized.
Taylor Hsu
Mr. Hsu joined Senhwa Biosciences in October 2025 as Business Development Director, where he is responsible for driving company growth by identifying and developing new business opportunities, as well as strengthening the company’s brand presence in global markets.
Mr. Hsu brings a strong background in oncology, with proven expertise in in-/out-licensing and extensive experience across the Southeast Asia, ANZ, and East Asia markets. He possesses deep insight into the pharmaceutical and biotechnology industries, with strong capabilities in market research and analysis, international business strategy, and financial and economic evaluation. Prior to joining Senhwa, Mr. Hsu served at TTY BioPharm, where he consistently delivered exceptional results and contributed significantly to the company’s success.
Mr. Hsu holds dual master’s degrees—an MBA from National Chengchi University, Taiwan and an MSc in Pharmacology from the University of Auckland—and has passed Chartered Financial Analyst (CFA) Level I test.
Kai-Wei Hsueh, PhD
Dr. Hsueh joined Senhwa in March 2023 and currently serves as the Deputy Director of the Clinical Department. In this role, he is responsible for studying the mechanisms of action, efficacy, safety, and toxicology of drugs. He has more than 10 years of experience in drug development. Prior to joining Senhwa, he worked as a Senior Scientist at OBI Pharma and HENLIX Biotech. Throughout his career, he has participated in numerous drug development projects and is well-versed in various bioanalytical methods, drug safety, and toxicology studies.
Dr. Hsueh graduated from Tatung University with a degree in Bioengineering and earned his Ph.D. from National Yang-Ming University in the Institute of Biochemistry and Molecular Biology.
